Savolitinib vs. Sunitinib in MET-driven PRCC.

Clinical trial NCT03091192 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03091192
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Carcinoma Carcinoma, Renal Cell Kidney Neoplasms Urologic Neoplasms Kidney Diseases Neoplasms by Site Enzyme Inhibitors Protein Kinase Inhibitors

Start date: 2017-07-25
Primary completion: 2019-08-18
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.